Breaking News Instant updates and real-time market news.

AMRN

Amarin

$2.68

-0.035 (-1.29%)

07:24
08/06/18
08/06
07:24
08/06/18
07:24

Amarin risk/reward favorable ahead of Q3 data, says Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen views the risk/reward for Amarin shares as favorable ahead of what she expects will be positive results for its Reduce-It outcomes study. Positive results from the study, which are expected by the end of Q3, should drive upward earnings revisions to levels not reflected in consensus numbers and the stock higher, Chen tells investors in a research note. The Street thinks Reduce-It will fail, the analyst adds. She affirms an Overweight rating on Amarin with a $10 price target.

AMRN Amarin
$2.68

-0.035 (-1.29%)

04/09/18
JEFF
04/09/18
NO CHANGE
Target $7
JEFF
Buy
Amarin risk/reward favorable into Q3 data, says Jefferies
Jefferies analyst Matthew Andrews surveyed 50 U.S. physicians and high prescribers of Amarin's Vascepa to assess current use of Vascepa in mixed dyslipidemia and severe high triglycerides, and future prescribing habits based on the REDUCE-IT data. The survey indicates Vascepa is the leading triglycerides-lowering drug in severe hypertriglyceridemia and mixed dyslipidemia, and positive MACE data in the REDUCE-IT trial could increase use 125% and 50%, respectively, Andrews tells investors in a research note. The analyst estimates peak-adjusted U.S. Vascepa sales of $1.06B by 2030. He sees a favorable risk/reward on Amarin shares into the Q3 data. The stock has upside to $7 on positive data and downside to $2.25 on a negative readout, Andrews contends. He keeps a Buy rating on Amarin with a $7 price target.
05/25/18
CANT
05/25/18
NO CHANGE
Target $10
CANT
Overweight
Amarin settlement terms with Teva favorable, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen believes the terms of the settlement agreement with Teva (TEVA) resolving Vascepa patent litigation are favorable to Amarin (AMRN). Under the settlement, Teva will not begin selling generic Vascepa in the U.S. until August 9, 2029, which is just six months off the expiry date of Vascepa's patents, Chen tells investors in a research note. She keeps an Overweight rating on Amarin with a $10 price target.
07/19/18
CANT
07/19/18
NO CHANGE
Target $10
CANT
Overweight
Amarin's Vascepa remains underappreciated, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen points out that Amarin's Reduce-It trial was highlighted in a Journal of the American review article titled "Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management." The analyst believes this supports her view that the market opportunity for Vascepa is still underappreciated. The paper highlights the unmet need for addressing residual risk for major adverse cardiovascular events even after intensive statin therapy, Chen tells investors in a research note. The analyst keeps an Overweight rating on Amarin shares with a $10 price target.
08/02/18
HCWC
08/02/18
NO CHANGE
Target $10
HCWC
Buy
Amarin risk/reward favorable into Reduce-It data, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein views the risk/reward profile on Amarin shares as "highly favorable" into the Reduce-It trial readout this September. The full value of Amarin resides with a successful trial outcome, Fein tells investors in a research note. He says he can "easily justify" a $14 price target with a 100% probability of success for the trial, representing 450% upside. If the trial is a miss, Fein says his price target would be $2, implying "only" 30% downside. He believes Vascepa may become the standard of care following Reduce-It outcome. The analyst keeps a Buy rating on Amarin with a $10 price target.

TODAY'S FREE FLY STORIES

14:15
03/20/19
03/20
14:15
03/20/19
14:15
General news
FOMC left the funds rate steady and dropped the 2019 dots to zero »

FOMC left the funds rate…

14:15
03/20/19
03/20
14:15
03/20/19
14:15
General news
Breaking General news story  »

Fed Chair Press…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.96

-1.52 (-0.54%)

14:07
03/20/19
03/20
14:07
03/20/19
14:07
General news
Fed to conclude reduction in securities holdings by end of September »

The Federal Reserve said…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.96

-1.52 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:07
03/20/19
03/20
14:07
03/20/19
14:07
General news
S&P turns positive after Fed stands pat, points to slow rate hike path »

Following the Federal…

14:05
03/20/19
03/20
14:05
03/20/19
14:05
General news
FOMC members lower median view of end 2019 funds rate to 2.4% »

The economic projections…

IMMU

Immunomedics

$18.37

-0.43 (-2.29%)

14:05
03/20/19
03/20
14:05
03/20/19
14:05
Options
Immunomedics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$281.02

-1.46 (-0.52%)

14:02
03/20/19
03/20
14:02
03/20/19
14:02
General news
Fed keeps federal funds target unchanged at 2.25% to 2.50% »

The Federal Reserve said…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$281.02

-1.46 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:02
03/20/19
03/20
14:02
03/20/19
14:02
General news
FOMC Meeting Announcement Federal Funds Rate data reported »

March FOMC Meeting…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$281.07

-1.41 (-0.50%)

14:01
03/20/19
03/20
14:01
03/20/19
14:01
General news
Fed says labor market remains strong, economic growth has slowed »

The Federal Reserve said…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$281.07

-1.41 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$281.04

-1.44 (-0.51%)

14:00
03/20/19
03/20
14:00
03/20/19
14:00
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Federal Reserve keeps…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$281.04

-1.44 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:55
03/20/19
03/20
13:55
03/20/19
13:55
General news
Treasury Action: yields remain lower prior to the FOMC announcemen »

Treasury Action: yields…

STZ

Constellation Brands

$164.46

-2.79 (-1.67%)

13:55
03/20/19
03/20
13:55
03/20/19
13:55
Conference/Events
Credit Suisse analysts to hold an analyst/industry conference call »

Analysts have a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 04

    Apr

BXC

BlueLinx

$25.79

0.13 (0.51%)

13:51
03/20/19
03/20
13:51
03/20/19
13:51
Conference/Events
BlueLinx management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

SPG

Simon Property

$173.53

0.11 (0.06%)

13:50
03/20/19
03/20
13:50
03/20/19
13:50
Options
Size put spread in Simon Property Group after a recent dip in shares »

Size put spread in Simon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRC

California Resources

$26.48

1.33 (5.29%)

13:45
03/20/19
03/20
13:45
03/20/19
13:45
Options
California Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
03/20/19
03/20
13:45
03/20/19
13:45
General news
Breaking General news story  »

FOMC Forecasts to be…

13:45
03/20/19
03/20
13:45
03/20/19
13:45
General news
FOMC Meeting Announcement Federal Funds Rate to be reported at 14:00 »

FOMC Meeting Announcement…

PLXS

Plexus

$60.65

-0.48 (-0.79%)

13:44
03/20/19
03/20
13:44
03/20/19
13:44
Initiation
Plexus initiated  »

Plexus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

HIIQ

Health Insurance Innovations

$30.11

-2.52 (-7.72%)

13:40
03/20/19
03/20
13:40
03/20/19
13:40
Recommendations
Health Insurance Innovations analyst commentary  »

Cantor calls Aurelius…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

LEVI

Levi Strauss

$0.00

(0.00%)

13:35
03/20/19
03/20
13:35
03/20/19
13:35
Periodicals
Levi Strauss IPO over 10 times oversubscribed, CNBC reports »

Levi Strauss'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

WLL

Whiting Petroleum

$25.97

1.38 (5.61%)

13:25
03/20/19
03/20
13:25
03/20/19
13:25
Options
Whiting Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Apr

SPY

SPDR S&P 500 ETF Trust

$280.91

-1.57 (-0.56%)

, SPX

S&P 500

$0.00

(0.00%)

13:17
03/20/19
03/20
13:17
03/20/19
13:17
Periodicals
Trump says tariffs on Chinese goods could stay for a long time, WSJ says »

U.S. President Donald…

SPY

SPDR S&P 500 ETF Trust

$280.91

-1.57 (-0.56%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
03/20/19
03/20
13:17
03/20/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
03/20/19
03/20
13:16
03/20/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$71.54

0.15 (0.21%)

13:15
03/20/19
03/20
13:15
03/20/19
13:15
Hot Stocks
Starbucks CEO says company focused on building foundation for next 50 years »

Starbucks CEO Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.